EligibleTrials

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

Recruiting · NCT07645820 · Observational (researchers observe without assigning treatment) · Lead sponsor: Castle Biosciences Incorporated

View the official record on ClinicalTrials.gov →
Eczema

Interventions studied

Nevisense electrical impedance spectroscopy

What this trial is about

This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.

Who can take part

Age range
12 Years to 89 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

10 locations listed across 9 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.